Myriad Genetics, Inc.

MYGNNASDAQHealthcareDiagnostics & Research

$4.35- (-)1Y −46.16%

As of Oct 15, 2026 close

Market cap: $412.38M
P/E (TTM): -
Forward P/E: -
Dividend yield: -
52-week range: $2.74$8.59
Volume (live): -
Avg. volume (3M): 1.96M

Myriad Genetics, Inc. (MYGN) Analyst Forecast

Analyst consensus ratings, 12-month price targets, and expert recommendations for Myriad Genetics, Inc. stock.

Analyst Consensus Rating

Investment consensus from 9 professional research analysts

Consensus Rating

Hold

Based on 9 unique analysts

Medium Confidence0.7:1 Buy/Sell

Average Price Target

$3.76

−13.56% downside

Loading chart...

Strong Sell

Sell

Hold

Buy

Strong Buy

Latest MYGN Analyst Ratings & Recommendations

Recent analyst recommendations with rating changes and price target updates (last 90 days)

Date	Analyst	Firm	Action	Rating	Price Target
Oct 2, 2026	William Bonello	Craig-Hallum	Maintains	Buy	$4.00 → $8.00 +4.00 (+100.0%)
Sep 9, 2026	Unknown Analyst	UBS	Initiates	Hold	$6.00 → $3.60 −2.40 (−40.0%)
Sep 1, 2026	David Westenberg	Piper Sandler	Downgrades	Sell	$8.50 → $2.00 −6.50 (−76.5%)
Aug 21, 2026	Unknown Analyst	Jefferies	Maintains	Sell	$2.50
Aug 18, 2026	Mason Carrico	Stephens	Reiterates	Hold	$3.00
Aug 4, 2026	Unknown Analyst	Guggenheim	Maintains	Hold	-
Aug 3, 2026	Michael Ryskin	BofA Securities	Reiterates	Sell	$4.00 → $3.20 −0.80 (−20.0%)
Jul 31, 2026	Kyle Boucher	TD Cowen	Reiterates	Hold	$6.00 → $4.00 −2.00 (−33.3%)
Jul 20, 2026	Ekta Bagri	Zacks Equity Research	Initiates Coverage	Buy	-

William Bonello

Craig-Hallum

BuyMaintains

$4.00 → $8.00

Oct 2

Unknown Analyst

UBS

HoldInitiates

$6.00 → $3.60

Sep 9

David Westenberg

Piper Sandler

SellDowngrades

$8.50 → $2.00

Sep 1

Unknown Analyst

Jefferies

SellMaintains

$2.50

Aug 21

Mason Carrico

Stephens

HoldReiterates

$3.00

Aug 18

Unknown Analyst

Guggenheim

HoldMaintains

Aug 4

Michael Ryskin

BofA Securities

SellReiterates

$4.00 → $3.20

Aug 3

Kyle Boucher

TD Cowen

HoldReiterates

$6.00 → $4.00

Jul 31

Ekta Bagri

Zacks Equity Research

BuyInitiates Coverage

Jul 20

Source: Professional analyst ratings and price targets from the last 90 days. Data as of Oct 2, 2026. Data sources and methodology

Frequently Asked Questions

What is the analyst consensus rating for MYGN?

The analyst consensus rating for MYGN is Hold, based on the latest ratings from 9 analysts over the last 90 days.

What is the average price target for MYGN?

The average 12-month price target for MYGN is $3.76, representing a downside of 13.6% from the Oct 15, 2026 close of $4.35.

What do analyst ratings mean?

Analyst ratings indicate investment recommendations: Strong Buy and Buy are bullish signals suggesting the stock may outperform. Hold means the stock is fairly valued. Sell and Strong Sell are bearish signals suggesting potential underperformance. These ratings are based on fundamental analysis and valuation models.

What is a price target?

A price target is an analyst's projection of a stock's fair value over a specific timeframe, typically 12 months. Analysts use fundamental analysis, financial modeling, and industry comparisons to estimate where the stock should trade. Price targets can range from low (conservative) to high (optimistic) estimates.